"We're thrilled to open our Oxford laboratory, which allows us to bring state-of-the-art NGS technology to UK researchers," said Dr Ginger Zhou, President of Azenta's Multiomics business unit.  "This new facility not only strengthens our global footprint but also offers researchers access to local experts and cutting-edge resources. The Oxford team comprises some of the best minds in the field, all with deep roots in the local scientific community." The opening event, held on April 25, 2024, featured a ribb ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04-30 ...

Azenta, Inc. (NASDAQ:AZTA) Q2 2024 Results Conference Call May 8, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants David Saxon - Needham Hannah Hefley - Stephens Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley Matt Stanton - Jefferies Operator Greetings, and welcome to the Azenta Second Quarter 2024 Financial Results. [Operator Instructions ...

Exhibit 99.1 Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024 BURLINGTON, Mass., May 8, 2024 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2024. | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------|-------|----------------------|-------|-------------------------|---------|------------------------------|----------------------|-------------| | Dollars in ...

CEO Dr. Stephen Schwartz to Retire; Search Underway to Identify Successor BURLINGTON, Mass., May 8, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a CEO succession plan, under which CEO and Board Director Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service. Dr. Schwartz will continue to serve as CEO until a successor is appointed to ensure a smooth transition. Dr. Schwartz's retirement follows a discussion with the Board as part of the company's active suc ...

BURLINGTON, Mass., April 1, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2023. The report offers a comprehensive look at the Company's ESG approach and showcases accomplishments in three main pillars: Environmenta ...

Financial Performance - Azenta's Q1 2024 revenue was $154 million, a 13% year-over-year decrease and a 15% decrease on an organic basis[7] - Non-GAAP EPS for Q1 2024 was $0.02, with an adjusted EBITDA of 30%[7] - The company's gross profit decreased from $81 million to $67 million, resulting in a gross profit margin decrease of 19 percentage points from 454% to 435%[9] - Azenta generated $15 million of free cash flow in Q1, marking the third consecutive quarter of positive free cash flow[7] Segment Performance - Sample Management Solutions (SMS) revenue reached $79 million, showing a 5% year-over-year increase, but only a 1% organic growth[12] - Excluding Consumables & Instruments (C&I), SMS organic growth was 9% year-over-year[8] - Multiomics revenue was $63 million, a 3% year-over-year increase, with 2% organic growth[15] - B Medical Systems experienced a 70% year-over-year revenue decline, primarily due to order timing in the vaccine cold chain[8] Balance Sheet and Capital Allocation - Azenta maintains a strong balance sheet with a cash balance of $11 billion as of December 31, 2023[7] - The company returned $113 million of capital through the repurchase of 23 million shares in Q1[7] - Approximately $500 million in cash remains available for disciplined and long-term value-creating initiatives after committed repurchases[7] Fiscal Year 2024 Guidance - Azenta anticipates organic revenue growth of 5% to 8%, with revenue projected between $696 million and $718 million[19] - The company expects an approximate 300 basis point margin improvement in adjusted EBITDA[19]

Azenta, Inc. (NASDAQ:AZTA) Q1 2024 Earnings Conference Call February 7, 2024 4:30 PM ET Company Participants Sara Silverman - Head of Investor Relations Stephen Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants David Saxon - Needham Jacob Johnson - Stephens Andrew Cooper - Raymond James Paul Knight - KeyBanc Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley Operator Greetings, and welcome to the Azenta Q1 2024 Financial Results. [Operator Instr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04 ...

Company Overview - Azenta Inc is a leading global provider of life sciences solutions, enabling faster breakthroughs and therapies to market [2] - The company offers a full suite of cold-chain sample management solutions and multiomics services across drug development, clinical research, and advanced cell therapies [2] - Azenta serves top pharmaceutical, biotech, academic, and healthcare institutions worldwide [2] - The company operates globally with headquarters in Burlington, MA and operations in North America, Europe, and Asia [2] - Azenta's portfolio includes industry-leading brands such as GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems [2] Investor Relations - Azenta will host an Investor Day on March 14, 2024 in New York City [1] - The event will feature presentations from the executive leadership team outlining the company's strategy and vision [1] - A live webcast of the Investor Day will be available on Azenta's website from 9:00 AM to 12:00 PM ET [1] - A replay of the audio webcast will be accessible on the website after the event concludes [1] Contact Information - Sara Silverman serves as Head of Investor Relations & Corporate Communications [3] - Sherry Dinsmore is another key contact for investor relations [3]